Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies to address the challenges posed by rare and serious blood disorders
Through rigorous research and advanced drug development, the company aims to create targeted therapies that improve patient outcomes and quality of life. With a strong emphasis on scientific innovation and collaboration, Disc Medicine seeks to harness the latest advancements in medical science to bring transformative treatments from the lab to the clinic, ultimately striving to make a significant impact in the field of hematology.
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.3% on Monday. The Dow traded down 0.67% to 39,538.91 while the NASDAQ fell 0.06% to 16,369.44. The S&P 500 also fell, dropping, 0.30% to 5,238.49.
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.
U.S. stocks traded lower midway through trading, with the Dow Jones falling over 300 points on Monday. The Dow traded down 0.79% to 39,492.80 while the NASDAQ fell 0.22% to 16,344.11. The S&P 500 also fell, dropping, 0.45% to 5,230.46.
Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin treatment.
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global rights for Roxadustat to FibroGen.
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash.
Gainers Asset Entities Inc. (NASDAQ: ASST) shares jumped 142% to $2.79 after the company announced the development of an AI bot as part of its AE360DDM suite of services on Discord.
